Observations placeholder

Strontium-89 is an isotope of strontium. Strontium-89 is a beta particle emitter with a half-life of 50 days.

Physiological effects and Medical use

Metastron, a preparation of strontium-89 chloride is an artificial radioisotope which is  used in treatment of bone cancer. In circumstances where cancer patients have widespread and painful bony metastases, the administration of 89Sr results in the delivery of beta particles directly to the area of bony problem, where calcium turnover is greatest.

89Sr, used in the treatment of osseous (bony) metastases preferentially targets metabolically active regions of the bone.   As such, intravenous or intracavity administration of 89Sr may be helpful in the palliation of painful bony metastases, as it allows for targeted radiation to metastatic lesions, inducing apoptosis of cells, membrane and protein damage. Subsequently, bone pain resulting from cytokine release at the site of lesions, bone-associated nerve compression and stretching of the periosteum may be reduced.

Treatment with 89Sr is also used in patients with hormonally-resistant prostate cancer.

On Jan, 7, 2016: 372 people reported to have side effects when taking Metastron. Among them, 1 people (0.27%) has Hallucination.

Time on Metastron when people have Hallucination  :

Gender of people who have Hallucination when taking Metastron  :

On Jan, 7, 2016: 372 people reported to have side effects when taking Metastron. Among them, 12 people (3.23%) have Death.

Time on Metastron when people have Death  :

Gender of people who have Death when taking Metastron  :